Butterfly Network Inc Stock Price, News & Analysis

Butterfly Network (NYSE: BFLY), a digital health company specializing in portable, semiconductor-based ultrasound technology, has scheduled its first quarter 2025 financial results announcement for May 2, 2025 before market opening.

The company will host a conference call and webcast at 8:00 am ET on the same day, featuring Joseph DeVivo, President, CEO and Chairman of the Board, alongside Heather Getz, EVP and Chief Financial and Operations Officer. The call will be available in listen-only mode through the company's Investor Relations website, with telephone access options for both domestic and international callers.

A replay of the call will remain accessible until May 15, 2025.

Butterfly Network (NYSE: BFLY) announced that its Butterfly iQ3 ultrasound device was prominently featured in Episodes 12 and 13 of HBO Max's medical drama 'The Pitt'. The show depicts the device being used in critical trauma scenarios, particularly during a mass casualty event where traditional cart-based ultrasound equipment was replaced with Butterfly's handheld devices.

The episodes showcase the device's versatility in performing EFAST exams, blood flow evaluations, internal bleeding detection, and intracranial pressure assessments. CEO Joseph DeVivo highlighted that Butterfly devices are present in all top 100 U.S. health systems, indicating widespread adoption of the technology.

The unpaid product placement demonstrates Butterfly's growing recognition in healthcare, with the brand name becoming a verb among clinicians, according to VP of Marketing Jennifer Huang. The feature emphasizes the increasing role of Point-of-Care Ultrasound (POCUS) technology across medical specialties.

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Virtual Conference on March 18, 2025.

The company's leadership, including Joseph DeVivo (President, CEO & Chairman) and Heather Getz (EVP & Chief Financial and Operations Officer), will engage in one-on-one investor meetings and participate in a Fireside Chat scheduled for 11:20am EDT. Investors can access the Fireside Chat webcast through the Events & Presentations section of Butterfly's investor website.

Butterfly Network (NYSE: BFLY) reported strong Q4 2024 results with record quarterly revenue of $22.4 million, representing 35% year-over-year growth. The company achieved significant financial improvements, reducing Q4 net loss by 59% and net cash used in operations by 76%.

Key Q4 metrics include:

• U.S. revenue up 32% to $14.5 million
• International revenue increased 19% to $5.5 million
• Product revenue grew 45% to $14.7 million
• Gross margin improved to 61.4%

The company successfully completed a public offering in January 2025, raising $81.7 million in net proceeds. Looking ahead, Butterfly provided FY2025 guidance of $96-100 million in revenue (approximately 20% growth) and adjusted EBITDA loss of $37-42 million.

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound and intuitive software, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025.

Heather Getz, Executive Vice President & Chief Financial and Operations Officer, will represent the company by conducting one-on-one investor meetings and delivering a business overview presentation scheduled for 1:10pm EST. Interested parties can access the presentation webcast through the Events & Presentations section of Butterfly's investor website.

Butterfly Network (NYSE: BFLY), a digital health company specializing in portable, semiconductor-based ultrasound technology, has scheduled its fourth quarter and full year 2024 financial results announcement for February 28, 2025, at 8:00 am ET.

The company's President, CEO and Chairman Joseph DeVivo, along with EVP and CFO Heather Getz, will host a conference call and webcast before market opening. The event will be accessible via webcast on Butterfly's Investor Relations website, with telephone access available for both domestic (1-877-300-8521) and international (1-412-317-6026) callers.

Butterfly Network (NYSE: BFLY) has announced the pricing of an underwritten public offering of 24,000,000 shares of Class A common stock at $3.15 per share, expected to generate gross proceeds of approximately $75.6 million. The company has granted underwriters a 30-day option to purchase up to an additional 3,600,000 shares at the same price.

The proceeds will be used to fund the development and commercialization of new and existing products and services, as well as for general corporate purposes. The offering, managed by bookrunners TD Cowen, William Blair, and Lake Street Capital Markets, is expected to close on January 31, 2025.

Butterfly Network (NYSE: BFLY) has announced the commencement of an underwritten public offering of Class A common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering. The net proceeds will be used to fund development and commercialization of new and existing products and services, as well as general corporate purposes.

TD Cowen, William Blair, and Lake Street Capital Markets are serving as bookrunners for the proposed offering, which is subject to market conditions. The offering is being made pursuant to a shelf registration statement on Form S-3 that became effective on August 22, 2023. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.

Butterfly Network (NYSE: BFLY) announced preliminary findings from a key study conducted with Rutgers Robert Wood Johnson Medical School, showing significant benefits of point-of-care ultrasound (POCUS) in hospital care. The study, presented at EchoEuro-Imaging Conference, focused on using cardiopulmonary POCUS for patients with unexplained shortness of breath.

The research compared hospital physicians using Butterfly iQ+ and iQ3 POCUS devices versus those not using POCUS. Key findings revealed substantial reductions in hospital length of stay (LOS): lower-acuity patients' LOS decreased from 6.7 to 5.6 days, while higher-acuity patients saw reduction from 39 to 16.7 days. Lower-acuity patients experienced up to 50% cost reduction. Daily lung ultrasound usage was identified as important for accelerating patient discharge.

The complete study is expected to be published in the first half of 2025.